Literature DB >> 22391071

Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence?

Sarah K Wise1, Rodney J Schlosser.   

Abstract

BACKGROUND: Increasing interest in sublingual immunotherapy (SLIT) among practitioners and patients has resulted in numerous publications and clinical trials in recent years. With the clinical growth of SLIT, discussions of its efficacy, safety, and immunologic effects have intensified, as have comparisons to subcutaneous immunotherapy (SCIT). In the United States, SCIT has been the traditional form of immunotherapy for inhalant allergy and is the only immunotherapy method approved by the U.S. Food and Drug Administration at this time. The similarities and differences between SLIT and SCIT are often discussed, yet clinical studies directly comparing these immunotherapy methods are scarce.
METHODS: A literature review of specific issues and controversies between SLIT and SCIT for allergic rhinitis was conducted.
RESULTS: Safety, efficacy, and immunologic effects of these two immunotherapy techniques are reviewed.
CONCLUSION: Unanswered questions relating to SLIT are examined.

Entities:  

Mesh:

Year:  2012        PMID: 22391071      PMCID: PMC3906519          DOI: 10.2500/ajra.2012.26.3691

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  46 in total

1.  Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study.

Authors:  M S Khinchi; L K Poulsen; F Carat; C André; A B Hansen; H-J Malling
Journal:  Allergy       Date:  2004-01       Impact factor: 13.146

2.  Systemic reactions from allergen immunotherapy.

Authors:  G E Stewart; R F Lockey
Journal:  J Allergy Clin Immunol       Date:  1992-10       Impact factor: 10.793

3.  Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study.

Authors:  Maurizio Marogna; Igino Spadolini; Alessandro Massolo; Giorgio Walter Canonica; Giovanni Passalacqua
Journal:  J Allergy Clin Immunol       Date:  2010-10-12       Impact factor: 10.793

4.  Summary health statistics for U.S. adults: National Health Interview Survey, 2009.

Authors:  John R Pleis; Brian W Ward; Jacqueline W Lucas
Journal:  Vital Health Stat 10       Date:  2010-12

Review 5.  Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis.

Authors:  Danilo Di Bona; Antonella Plaia; Valeria Scafidi; Maria Stefania Leto-Barone; Gabriele Di Lorenzo
Journal:  J Allergy Clin Immunol       Date:  2010-08-01       Impact factor: 10.793

6.  Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite.

Authors:  G K Scadding; J Brostoff
Journal:  Clin Allergy       Date:  1986-09

7.  Sublingual immunotherapy in children with allergic polysensitization.

Authors:  Giorgio Ciprandi; Geovanni Cadario; Giuseppe M Di Gioacchino; Salvatore Gangemi; Alberto Gasparini; S Isola; Fulvia Marengo; Salvatore Minelli; Leopoldo Ricciardi; Erminia Ridolo; Valerio Pravettoni; Carla Valle; Marcello Verini; Marcello Zambito; Cristoforo Incorvaia; Paola Puccinelli; Silvia Scurati; Franco Frati; Masieri Simonetta
Journal:  Allergy Asthma Proc       Date:  2010 May-Jun       Impact factor: 2.587

8.  Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

Authors:  David I Bernstein; Mark Wanner; Larry Borish; Gary M Liss
Journal:  J Allergy Clin Immunol       Date:  2004-06       Impact factor: 10.793

9.  Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.

Authors:  A O Eifan; T Akkoc; A Yildiz; S Keles; C Ozdemir; N N Bahceciler; I B Barlan
Journal:  Clin Exp Allergy       Date:  2010-01-20       Impact factor: 5.018

Review 10.  Sublingual immunotherapy for allergic rhinitis.

Authors:  Suzana Radulovic; Moises A Calderon; Duncan Wilson; Stephen Durham
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08
View more
  7 in total

1.  Response.

Authors:  Joshua L Kennedy; Larry Borish; Jared Christophel; Spencer C Payne
Journal:  Am J Rhinol Allergy       Date:  2014 Jul-Aug       Impact factor: 2.467

Review 2.  Exposure to dog allergens and subsequent allergic sensitization: an updated review.

Authors:  Jordan Smallwood; Dennis Ownby
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

3.  Three-Year Follow-up Results of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitized to House Dust Mites.

Authors:  Shin Hye Kim; Sue Jean Mun; Doo Hee Han; Jeong-Whun Kim; Dong-Young Kim; Chae-Seo Rhee
Journal:  Allergy Asthma Immunol Res       Date:  2014-10-30       Impact factor: 5.764

Review 4.  Is The Allergen Really Needed in Allergy Immunotherapy?

Authors:  Thomas M Kündig; Ludger Klimek; Philipp Schendzielorz; Wolfgang A Renner; Gabriela Senti; Martin F Bachmann
Journal:  Curr Treat Options Allergy       Date:  2015

Review 5.  Variation in allergen content in sublingual allergen immunotherapy with house dust mites.

Authors:  F Moreno Benítez; M Espinazo Romeu; A Letrán Camacho; S Mas; F J García-Cózar; A I Tabar
Journal:  Allergy       Date:  2015-09-11       Impact factor: 13.146

Review 6.  Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases.

Authors:  Ludger Klimek; Thomas Kündig; Matthias F Kramer; Sonja Guethoff; Erika Jensen-Jarolim; Carsten B Schmidt-Weber; Oskar Palomares; Mona O Mohsen; Thilo Jakob; Martin Bachmann
Journal:  Allergo J Int       Date:  2018-07-09

7.  Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy.

Authors:  Qingliang Kong; Kouki Higasijima; Rie Wakabayashi; Yoshiro Tahara; Momoko Kitaoka; Hiroki Obayashi; Yanting Hou; Noriho Kamiya; Masahiro Goto
Journal:  Pharmaceutics       Date:  2019-10-30       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.